BNC-420

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameBNC-420
Drug Alias Namereceptor kinase modulators (Cancer Therapeutics CRC)CTx-0357927VEGFR-3 inhibitors (Cancer Therapeutics CRC/Bionomics)VEGFR-3 inhibitors (Cancer Therapeutics CRC)BL-011256 +[6] 
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitorsVascular endothelial growth factor receptor 3 antagonists
TargetsVascular endothelial growth factor receptor 3
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Therapeutics CRC Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCancer Therapeutics CRC Pty LtdBionomics Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursBreast NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A